Moderna, Inc. (MRNA) Earnings
Moderna, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Jul 31, 2026
From the latest earnings 8-K
Revenue · FY2025
$1.94B
▼ 39.9%YoY
Diluted EPS · FY2025
$-7.26
▲ 21.8%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from MRNA's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.94B | -$2.82B | — | $-7.26 | -$2.06B | -158.1% | -39.9% |
| FY2024 | $3.24B | -$3.56B | — | $-9.28 | -$4.05B | -121.9% | -52.8% |
| FY2023 | $6.85B | -$4.71B | — | $-12.33 | -$3.83B | -61.9% | -64.5% |
| FY2022 | $19.26B | $8.36B | — | $20.12 | $4.58B | 48.9% | +4.3% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Jul 31, 2026 | 8-K (2.02) | 0001682852-26-000147EDGAR |
| May 1, 2026 | 8-K (2.02) | 0001682852-26-000057EDGAR |
| Feb 13, 2026 | 8-K (2.02) | 0001682852-26-000015EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001682852-26-000007EDGAR |
| Nov 6, 2025 | 8-K (2.02) | 0001682852-25-000073EDGAR |
| Aug 1, 2025 | 8-K (2.02) | 0001682852-25-000041EDGAR |
| May 1, 2025 | 8-K (2.02) | 0001682852-25-000031EDGAR |
| Feb 14, 2025 | 8-K (2.02) | 0001682852-25-000006EDGAR |
Never miss a MRNA filing.
Get an email when MRNA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Sep 16, 2026Source: SEC EDGAR.